# UgenTec NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ugentec

- Industry: Healthcare IT
- Headquarters: Hasselt, Belgium
- Website: www.ugentec.com
- Total disclosed funding: $6.1M
- Latest round: Series A (Apr 5, 2018)
- Investors on record: 4

## About

UgenTec NV is a Belgium-based provider of laboratory software solutions for molecular diagnostics, focusing on automation and data analysis to enhance laboratory efficiency and accuracy.Founded in 2014 in Hasselt, Belgium, UgenTec NV specializes in developing advanced software for molecular diagnostics. The company was founded by Tom Martens and Wouter Uten. UgenTec has secured EUR 7.50 mn in funding over its Series A round, which concluded on September 7, 2022, with investors including HERAN Partners, K.U. Leuven Research & Development, LRM, and imec.istart. The total amount raised to date is EUR 7.50 mn.UgenTec, now operating as Velsera, specializes in providing a comprehensive suite of laboratory software solutions tailored for molecular diagnostics. Their flagship offerings include the FastFinder platform, which encompasses various tools such as FastFinder Workflow, FastFinder Analysis, FastFinder Insights, FastFinder QC, and FastFinder Genotyper. These products streamline laboratory operations by automating sample workflows, result calling, quality control, and data analysis, delivering reliable and reproducible results crucial for clinical decision-making. The FastFinder platform is designed for clinical laboratories, assay providers, and research institutions, enhancing efficiency and accuracy in testing processes for a broad range of applications, including infectious disease diagnostics, oncology, and pharmacogenomics. UgenTec serves a global client base, with implementations across North America, Europe, and Asia, positioning itself as a key player in the molecular diagnostics market.In 2022, UgenTec reported revenue of EUR 10,521,020.70 and an EBITDA of EUR 2,952,736.10. The company generates revenue primarily through its software solutions, which are typically offered on a subscription basis. This transactional structure allows clients, including clinical laboratories and research institutions, to access the FastFinder platform and its suite of tools under a recurring payment model.Following a majority stake acquisition by Summa Equity in September 2022, UgenTec NV aims to capitalize on its established growth and innovation in molecular diagnostics. The recent funding will support the development of new products and enhancements to the FastFinder platform, further expanding its capabilities. UgenTec plans to penetrate additional markets in North America and Asia by 2024, leveraging this investment to meet the increasing demand for efficient laboratory solutions.

## Funding rounds

- Series A, Apr 5, 2018, $5.1M — K.U. Leuven Research & Development, LRM, imec.istart, HERAN Partners
- Series A, Apr 10, 2015, $1.1M — K.U. Leuven Research & Development

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Series A
- LRM (https://capitalatlas.ai/funds/lrm) — Series A
- imec.istart — Series A
- HERAN Partners (https://capitalatlas.ai/funds/heran-partners) — Series A